Parkinson's Disease

Rivastigmine

Placebo (for rivastigmine)

Related info, instructions for inclusion and study protocol

Academic Medical Center

University Medical Center Groningen

Atrium Medical Center

University Medical Center St Radboud

Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s Disease

Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson's Disease:a Multi-center Placebo-controlled Trial.

the time until Parkinson's disease patients with minor visual hallucinations progress to major visual hallucinations without insight (according to UPDRS 1 - MDS). The clinical endpoint is defined as the start with antipsychotic treatment.

change in motor control measured by UPDRS 3 - MDS

change in occurence or severity of psychotic symptoms according to Scale of Assessment of Positive Symptoms (SAPS) and UPDRS 1 MDS.

change in cognitive function as measured by Mini Mental State Examination, Montreal Cognitive Assessment, Parkinson's Disease - Cognitive Rating Scale

Mood disturbance according to the Hospital Anxiety and Depression Scale

Daytime sleepiness on the Epworth Sleepiness Scale

Cholinergic deficiency, as a possible predictor for response to treatment, measured with the Cholinersterase Inhibitor Prognosticator

Compliance to treatment measured by the number of remaining capsules after every 6 months of follow-up

Disability based on the AMC Linear Disability Score

Caregiver burden according to the Zarit Caregiver Burden Inventory

functional connectivity (phase lag index)

topological network organisation (minimum spanning tree)

direction of information flow (directed phase lag index)

Tom van Mierlo

drs T.J.M. van Mierlo

VU University Medical Center

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Leiden University Medical Center

University Medical Center Nijmegen

International Parkinson Fonds Germany GmbH

ZonMw: The Netherlands Organisation for Health Research and Development

Ataxia

Chorea

Dystonia

Parkinsonism

Fatigue

amantadine 5/mg/kg for 2 month- tapered up during 2 weeks at 1 month possibility to increase dosage to 8 mg/kg or reduce it if there are side effects

hypokinesia/повръщане

Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s Disease

Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia

Най-пълната база данни за лечебни билки, подкрепена от науката